Indication
Acute leukemia with lysine methyltransferase 2A gene (KMT2A) translocation
Acute leukemia with lysine methyltransferase 2A gene (*KMT2A*) translocation is an aggressive hematologic malignancy affecting the blood and bone marrow in pediatric, adult, and particularly infant populations. Read more about Acute leukemia with lysine methyltransferase 2A gene (KMT2A) translocation
1 drugs 1 manufacturers
Drugs that treat it
Common Acute leukemia with lysine methyltransferase 2A gene (KMT2A) translocation therapies.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAcute leukemia with lysine methyltransferase 2A gene (*KMT2A*) translocation is an aggressive hematologic malignancy affecting the blood and bone marrow in pediatric, adult, and particularly infant populations.
The disease spans acute myeloid leukemia, acute lymphoblastic leukemia, and mixed-phenotype acute leukemia, defined cytogenetically by balanced chromosomal rearrangements at chromosome band 11q23.
Pathophysiologically, these translocations create chimeric fusion oncoproteins that recruit epigenetic regulators to aberrantly upregulate critical oncogenic transcription programs, notably *HOXA* cluster genes and *MEIS1*.
This molecular mechanism results in blocked hematopoietic differentiation, uncontrolled blast proliferation, marked chemoresistance, and an unfavorable clinical prognosis.
- nih.gov
Acute leukemia with lysine methyltransferase 2A gene (*KMT2A*) translocation is an aggressive hematologic malignancy affecting the blood and bone marrow in pediatric, adult, and particularly infant populations The disease spans acute myeloid leukemia, acute lymphoblastic leukemia, and mixed-phenotype acute leukemia, defined cytogenetically by balanced chromosomal rearrangements at chromosome band 11q23 This molecular mechanism results in blocked hematopoietic differentiation, uncontrolled blast ...
- nih.gov
Acute leukemia with lysine methyltransferase 2A gene (*KMT2A*) translocation is an aggressive hematologic malignancy affecting the blood and bone marrow in pediatric, adult, and particularly infant populations
- haematologica.org
Acute leukemia with lysine methyltransferase 2A gene (*KMT2A*) translocation is an aggressive hematologic malignancy affecting the blood and bone marrow in pediatric, adult, and particularly infant populations
- nih.gov
The disease spans acute myeloid leukemia, acute lymphoblastic leukemia, and mixed-phenotype acute leukemia, defined cytogenetically by balanced chromosomal rearrangements at chromosome band 11q23 Pathophysiologically, these translocations create chimeric fusion oncoproteins that recruit epigenetic regulators to aberrantly upregulate critical oncogenic transcription programs, notably *HOXA* cluster genes and *MEIS1*
- wikipedia.org
The disease spans acute myeloid leukemia, acute lymphoblastic leukemia, and mixed-phenotype acute leukemia, defined cytogenetically by balanced chromosomal rearrangements at chromosome band 11q23
- atlasgeneticsoncology.org
The disease spans acute myeloid leukemia, acute lymphoblastic leukemia, and mixed-phenotype acute leukemia, defined cytogenetically by balanced chromosomal rearrangements at chromosome band 11q23
- nih.gov
Pathophysiologically, these translocations create chimeric fusion oncoproteins that recruit epigenetic regulators to aberrantly upregulate critical oncogenic transcription programs, notably *HOXA* cluster genes and *MEIS1* This molecular mechanism results in blocked hematopoietic differentiation, uncontrolled blast proliferation, marked chemoresistance, and an unfavorable clinical prognosis
- nih.gov
This molecular mechanism results in blocked hematopoietic differentiation, uncontrolled blast proliferation, marked chemoresistance, and an unfavorable clinical prognosis
Personalize your experience
Follow Acute leukemia with lysine methyltransferase 2A gene (KMT2A) translocation and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.